OS Therapies Inc
Research OS Therapies Inc (OSTX) on Bullrun: market cap USD 74.72M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOSTX
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 74.72M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 10.40M
- Free cash flow-USD 4.56M
Valuation Snapshot
latest market cap is USD 74.72M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 28.75M | -USD 14.70M | n/a | -0.98 | USD 269.83K | n/a | -USD 6.10M |
| FY2024 | USD 0 | -USD 8.88M | -USD 7.28M | n/a | -1.28 | USD 5.53M | USD 16.70M | -USD 3.27M |
| FY2023 | n/a | -USD 7.79M | n/a | n/a | -1.46 | USD 38.98K | USD 14.61M | -USD 24.02M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 74.72M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 51.96M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 89.32M | n/a | n/a | n/a |
About OS Therapies Inc
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is OS Therapies Inc's market cap?
OS Therapies Inc's market capitalization is USD 74.72M.
What does OS Therapies Inc do?
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.